Data completeness
0/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLUIDIL (cyclothiazide) is an oral thiazide diuretic tablet approved as a new drug application (NDA) by Pfizer, currently in pre-launch phase. Cyclothiazide is a thiazide-class diuretic used primarily for hypertension and edema management. The drug works by inhibiting sodium reabsorption in the distal convoluted tubule, promoting diuresis and reducing blood pressure.
Pre-Launch
Early-stage launch preparation; commercial team size will expand as pre-launch transitions to market entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FLUIDIL careers are concentrated in pre-launch infrastructure roles: regulatory, manufacturing readiness, and commercial strategy. As launch approaches, opportunities will expand across sales, medical affairs, and brand management, with team growth tied to market entry timeline and competitive intensity.
Brand ManagerProduct Manager
Worked on FLUIDIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.